Dempze Nancy E buys $424,082 stake in Illumina (ILMN)

Illumina (ILMN) : Dempze Nancy E scooped up 810 additional shares in Illumina during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 2,524 shares of Illumina which is valued at $424,082.Illumina makes up approximately 0.73% of Dempze Nancy E’s portfolio.

Other Hedge Funds, Including , Advisors Asset Management reduced its stake in ILMN by selling 1,263 shares or 5.64% in the most recent quarter. The Hedge Fund company now holds 21,126 shares of ILMN which is valued at $3,549,591. Illumina makes up approx 0.06% of Advisors Asset Management’s portfolio.Reilly Financial Advisors reduced its stake in ILMN by selling 86 shares or 86.0% in the most recent quarter. The Hedge Fund company now holds 14 shares of ILMN which is valued at $2,311.Royal London Asset Management Ltd reduced its stake in ILMN by selling 2,667 shares or 5.11% in the most recent quarter. The Hedge Fund company now holds 49,568 shares of ILMN which is valued at $8,181,198. Illumina makes up approx 0.13% of Royal London Asset Management Ltd’s portfolio. Riverpark Capital Management added ILMN to its portfolio by purchasing 14,843 company shares during the most recent quarter which is valued at $2,449,837. Illumina makes up approx 1.11% of Riverpark Capital Management’s portfolio.

Illumina opened for trading at $167.4 and hit $174.48 on the upside on Monday, eventually ending the session at $173.36, with a gain of 3.81% or 6.37 points. The heightened volatility saw the trading volume jump to 14,12,693 shares. Company has a market cap of $25,415 M.

On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.

Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.